Drug Information

Drug General Information
Drug ID
D0G5WV
Former ID
DIB015477
Drug Name
KTE-C19 CAR
Indication Diffuse large B-cell lymphoma [ICD9: 200; ICD10:C83.3] Phase 1/2 [549522]
Company
Kite pharma santa monica; national cancer institute
Target and Pathway
Target(s) B-lymphocyte antigen CD19 Target Info Inhibitor [549913]
KEGG Pathway PI3K-Akt signaling pathway
Hematopoietic cell lineage
B cell receptor signaling pathway
Epstein-Barr virus infection
Primary immunodeficiency
NetPath Pathway IL-7 Signaling Pathway
PANTHER Pathway B cell activation
Pathway Interaction Database BCR signaling pathway
Reactome PIP3 activates AKT signaling
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Constitutive Signaling by Aberrant PI3K in Cancer
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
WikiPathways Human Complement System
Signaling by the B Cell Receptor (BCR)
PIP3 activates AKT signaling
B Cell Receptor Signaling Pathway
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
References
Ref 549522Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039436)
Ref 549913Clinical pipeline report, company report or official report of Kite Pharma.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.